Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C15H23N3O4S
Número CAS:
Peso molecular:
341.43
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
239-753-7
MDL number:
Form:
powder
Quality level:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
(±)-Sulpiride,
form
powder
Quality Level
color
white
solubility
45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 8.0 mg/mL, 0.1 M HCl: soluble, H2O: slightly soluble, ethanol: soluble
originator
Sanofi Aventis
storage temp.
2-8°C
SMILES string
CCN1CCCC1CNC(=O)c2cc(ccc2OC)S(N)(=O)=O
InChI
1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
InChI key
BGRJTUBHPOOWDU-UHFFFAOYSA-N
Gene Information
human ... CA1(759), CA2(760), CA4(762), CA5A(763), CA5B(11238), CA9(768), DRD2(1813)
Application
(±)-Sulpiride was used to study the effect of dopamine D2 receptor signaling on calcium channels in rat pituitary melanotropic cells.47
Biochem/physiol Actions
(±)-Sulpiride is a D2 dopamine antagonist and an effective treatment for schizophrenia when used in combination with clozapine, a relatively weak D2-dopaminergic antagonist. It is an antipsychotic agent and also exhibits neuroleptic properties but poorly penetrates the central nervous system.45,46
Features and Benefits
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Preparation Note
Solutions may be stored for several days at 4 °C.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
J A Keja et al.
The Journal of physiology, 450, 409-435 (1992-05-01)
1. Whole-cell voltage clamp recordings were made from 141 rat pituitary melanotropic cells in short-term, serum-free, primary culture. The effects of the dopamine D2 receptor agonist, LY 171555, on sodium, potassium and barium currents were investigated. 2. Application of 1
R Shiloh et al.
The British journal of psychiatry : the journal of mental science, 171, 569-573 (1998-03-31)
We hypothesised that a combined regimen of clozapine, a relatively weak D2-dopaminergic antagonist, and sulpiride, a selective D2 blocker, would demonstrate a greater antipsychotic efficacy by enhancing the D2 blockade of clozapine. Twenty-eight people with schizophrenia, previously unresponsive to typical
Giuseppina De Simone et al.
Journal of medicinal chemistry, 49(18), 5544-5551 (2006-09-01)
An approach for designing bioreductive, hypoxia-activatable carbonic anhydrase (CA, EC 4.2.1.1) inhibitors targeting the tumor-associated isoforms is reported. Sulfonamides incorporating 3,3'-dithiodipropionamide/2,2'-dithiodibenzamido moieties were prepared and reduced enzymatically/chemically in conditions present in hypoxic tumors, leading to thiols. The X-ray crystal structure
